Skin & Soft Tissue Diseases

Latest News


CME Content


Edmond LaVoie, PhD, professor and chair, Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers University, co-founder of TAXIS Pharmaceuticals, and co-author of the study on the new MRSA drug, TXA709, explains how TXA709 targets MRSA differently than other antibiotics.

Daniel Pilch, PhD, associate professor in the Department of Pharmacology at Rutgers Robert Wood Johnson Medical School, co-founder of TAXIS Pharmaceuticals, and co-author of the study, explains why MRSA is especially dangerous, and the effectiveness of the team’s new drug, TXA079.